1. Home
  2. RECT vs BCDA Comparison

RECT vs BCDA Comparison

Compare RECT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rectitude Holdings Ltd

RECT

Rectitude Holdings Ltd

SELL

Current Price

$1.27

Market Cap

17.7M

Sector

N/A

ML Signal

SELL

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.91

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RECT
BCDA
Founded
1997
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
15.7M
IPO Year
2023
2009

Fundamental Metrics

Financial Performance
Metric
RECT
BCDA
Price
$1.27
$0.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
4.6K
★ 114.1K
Earning Date
07-30-2026
11-16-2026
Dividend Yield
★ 7.94%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.74
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.96
$0.75
52 Week High
$2.90
$1.80

Technical Indicators

Market Signals
Indicator
RECT
BCDA
Relative Strength Index (RSI) 48.36 44.86
Support Level $1.07 $0.82
Resistance Level $1.39 $1.06
Average True Range (ATR) 0.11 0.08
MACD -0.01 -0.00
Stochastic Oscillator 22.67 29.33

Price Performance

Historical Comparison
RECT
BCDA

About RECT Rectitude Holdings Ltd

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: